Iconic Therapeutics Appoints Brandon Smith Chief Operating Officer
Source: Iconic Therapeutics
Wednesday, August 23, 2017 | Management/Leadership
Iconic Therapeutics announced the appointment of Brandon Smith as Chief Operating Officer. He joins Iconic from Impax Laboratories, where he served as Senior Vice President of Corporate Development and Strategy. Brandon brings to Iconic over 15 years of experience in public biotechnology companies, and has led a wide range of business and corporate development functions.
Brandon adds to the leadership team wide-ranging experience in licensing, alliance management, deal integration and portfolio management. Prior to Impax, he was an Executive Director at Amgen, where he led the business case team for Amgen’s entry into biosimilars and subsequently helped form the separate biosimilars business unit responsible for developing and partnering multiple active biosimilars programs in addition to holding positions of increasing responsibility in Operations, Corporate Strategy, and M&A. He has also been a Project Leader at the Boston Consulting Group and Production Engineer and Plant Supervisor at BASF Corporation. He received a B.S. degree in Chemical Engineering from the University of Michigan and an MBA from the McCombs Graduate School of Business.
“Brandon`s expertise complements our world-class group of senior leaders in research, manufacturing and clinical development. As we move into late-stage development following our successful phase 2a study in wet AMD with our lead asset ICON-1 and progress our oncology and research programs targeting Tissue Factor, his strategic insight and business partnering and commercialization expertise will be invaluable to us,” William Greene, MD, Chief Executive Officer, said in a company news release.
Dr. Greene further noted, “Iconic has the leadership team in place to advance our programs into and through all stages of development. Brandon will lead strategic alliance discussions for us on ICON-1 while Dr. Gabriela Burian, MD MPH, our committed Chief Medical Officer, continues to drive the clinical, regulatory and registrational strategy for Iconic’s lead program. With the encouraging results of our Phase 2a trial evaluating ICON-1 in Wet AMD, we are even more confident in the potential of our drug candidate to be truly disease-modifying and to provide more durable benefit in retinal disease. We anticipate a global program designed to address the significant unmet needs in the vision arena.”
You must be logged in to leave a comment.